Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 261 to 270 of 323

TitleTypeExpected publication date
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Technology appraisal guidanceTBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284Technology appraisal guidanceTBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All